Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study☆,☆☆
Keywords
Abbreviations
Cited by (0)
- ☆
Disclosures and acknowledgments: This research was supported by Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A/S. Editorial support for development of this manuscript was provided by Vandana Sharma, PhD, at C4 MedSolutions, LLC (Yardley, PA), a CHC Group company, and funded by Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A/S.
- ☆☆
Previous presentations: Long-term effectiveness of aripiprazole once-monthly is maintained in the QUALIFY extension study. Naber D, Eramo A, Forray C et al. Presented at: the Schizophrenia International Research Society Annual Scientific Meeting, April 2–4, 2016; Florence, Italy; the American Psychiatric Association Annual Meeting, May 14–18, 2016; Atlanta, GA; the American Society of Clinical Psychopharmacology Annual Meeting, May 30–June 3, 2016; Scottsdale, AZ.